BEAM
BEAM
NASDAQ · Biotechnology

Beam Therapeutics Inc

$26.38
+0.51 (+1.97%)
As of Nov 7, 1:37 AM ET ·
Financial Highlights (FY 2026)
Revenue
146.06M
Net Income
-83,612,088
Gross Margin
—
Profit Margin
-57.2%
Rev Growth
+31.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 48.9% 48.9%
Operating Margin -274.6% -247.1% -6.1% -6.1%
Profit Margin -57.2% -54.4% -9.9% -9.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 146.06M 110.75M 476.44M 432.89M
Gross Profit — — 233.13M 211.83M
Operating Income -401,044,380 -273,688,157 -29,234,950 -26,348,592
Net Income -83,612,088 -57,060,114 -46,993,180 -41,441,136
Gross Margin — — 48.9% 48.9%
Operating Margin -274.6% -247.1% -6.1% -6.1%
Profit Margin -57.2% -54.4% -9.9% -9.6%
Rev Growth +31.9% +31.9% -6.6% +15.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 420.07M 396.17M
Total Equity — — 1.92B 2.06B
D/E Ratio — — 0.22 0.19
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -377,743,040 -272,107,892 -41,088,618 -32,500,848
Free Cash Flow — — -33,034,013 -43,893,077